SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Vinnie who wrote (361)8/9/2000 1:02:09 AM
From: Vector1  Read Replies (1) of 496
 
Vinnie, it depends on the indication. How long it takes the drug to effect the disease state and the number of patients in the trial all have an impact. In addtion how long does it take to attract patients. If it is a metabolic disease for example the phase II could take years. If the indication on the other hand is acute pain the phase II is quick. With regard to the GLFD/AMGN phase II I would guess it will be 9 months to a year before we get results.
V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News